Jump to content

Follow Us:   Twitter Facebook Celiac.com Forum RSS      

Get email alerts  Subscribe to FREE Celiac.com email alerts
arrowShare this page:
Subscribe Today!

Celiac.com Sponsor:
Celiac.com Sponsor:


Member Since 26 Dec 2007
Offline Last Active Jul 29 2015 04:05 AM

Topics I've Started

To Fry Or Not To Fry, That Is The Question ? Turkey, That Is.

15 November 2014 - 04:42 PM

OK, they are selling turkey fryers all over the place it seems.  Is it a good idea to fry a turkey?  Anyone have experience good or bad in turkey frying?  Is it really much faster than oven baking/roasting?  Do you still stuff a turkey that is going to be fried?  Just looking for tips as I am thinking of getting a turkey fryer and trying it out.  They seem to be selling them everywhere this year.  Lowes, Aldi's prolly other places too.  Thanks for any advice. :)

Canyon Bakehouse Giveaway At Harris Whole Health

17 September 2014 - 05:04 AM

Cheryl Harris has posted about a Canyon Bakehouse bread giveaway on her website.




Basically you leave a comment about what you'd make with the bread on her website (at bottom of the page) or post the link to her page on FB or twitter to enter.  I think this will only work for USA peeps though.  I think the first thing I'd make is frozen bread since I'd want to eat it slowly.

Huge Medical Breakthrough! Scientists Discover How To "switch Off" Autoimmu...

03 September 2014 - 06:04 PM

A possible future treatment...  Not available for celiac now.



Huge Medical Breakthrough! Scientists Discover How to "Switch Off" Autoimmune Diseases

Phillippa Walker : Sep 3, 2014 : University of Bristol


(United Kingdom)—Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue.

Rather than the body's immune system destroying its own tissue by mistake, researchers at the University of Bristol have discovered how cells convert from being aggressive to actually protecting against disease.

The study, funded by the Wellcome Trust, was published September 3 in Nature Communications.

It's hoped this latest insight will lead to the widespread use of antigen-specific immunotherapy as a treatment for many autoimmune disorders, including multiple sclerosis (MS), type 1 diabetes, Graves' disease and systemic lupus erythematosus (SLE).

MS alone affects around 100,000 people in the UK and 2.5 million people worldwide.

Scientists were able to selectively target the cells that cause autoimmune disease by dampening down their aggression against the body's own tissues while converting them into cells capable of protecting against disease.

This type of conversion has been previously applied to allergies, known as 'allergic desensitization', but its application to autoimmune diseases has only been appreciated recently.

The Bristol group has now revealed how the administration of fragments of the proteins that are normally the target for attack leads to correction of the autoimmune response.

Most importantly, their work reveals that effective treatment is achieved by gradually increasing the dose of antigenic fragment injected.

In order to figure out how this type of immunotherapy works, the scientists delved inside the immune cells themselves to see which genes and proteins were turned on or off by the treatment.

They found changes in gene expression that help explain how effective treatment leads to conversion of aggressor into protector cells. The outcome is to reinstate self-tolerance whereby an individual's immune system ignores its own tissues while remaining fully armed to protect against infection.

By specifically targeting the cells at fault, this immunotherapeutic approach avoids the need for the immune suppressive drugs associated with unacceptable side effects such as infections, development of tumors and disruption of natural regulatory mechanisms.

Professor David Wraith, who led the research, said: "Insight into the molecular basis of antigen-specific immunotherapy opens up exciting new opportunities to enhance the selectivity of the approach while providing valuable markers with which to measure effective treatment. These findings have important implications for the many patients suffering from autoimmune conditions that are currently difficult to treat."

This treatment approach, which could improve the lives of millions of people worldwide, is currently undergoing clinical development through biotechnology company Apitope, a spin-out from the University of Bristol.



Celiac.com Sponsors: